GeneDx is trading 4.3% up at $67.91 as investors position ahead of its Q2 2026 earnings release.
- Market attention is focused on upcoming results regarding revenue, EPS loss, testing volumes, and margin trends.
- The stock saw significant momentum in pre-market trading, reaching a high of $69.01 earlier today.
- The upward move coincides with a broader risk-on rally across major U.S. indices, driven by easing geopolitical tensions and strong economic data.